Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Liman Huo
Institution:
Fourth Hospital of Hebei Medical University
Observed institution:
Fourth Hospital of Hebei Medical University
ORCID:
0000-0003-0078-4047
Observed ORCID:
0000-0003-0078-4047
OpenAlex ID:
A5083318383
Severe thyrotoxicosis induced by tislelizumab: a case report and literature review
2023
·
Liman Huo
, Chao Wang
, et al.
·
Frontiers in Oncology
·
13
PDF
Efficacy and safety of first-line targeted and immunotherapy for metastatic colorectal cancer: a network meta-analysis
2025
·
Liman Huo
, Hongyu Yue
, et al.
·
Frontiers in Immunology
·
5
Adoptive cellular immunotherapy combined with chemotherapy versus chemotherapy alone in Chinese patients with metastatic colorectal cancer: a cost-effectiveness analysis to inform drug pricing
2025
·
Liman Huo
, Ping Liang
, et al.
·
Frontiers in Oncology
·
2
PDF
Norvancomycin plasma concentration monitoring in hemodialysis patients with end stage kidney disease: A retrospective cohort study
2023
·
Liying Du
, Liman Huo
, et al.
·
Biopharmaceutics & Drug Disposition
·
2
Tranexamic acid inhibits mitochondrial DNA release and reduces inflammatory response in an in vitro model of OGD/R-induced Caco-2 cell injury
2026
·
Ziyue Wang
, Liman Huo
, et al.
·
BMC Pharmacology and Toxicology
·
1
Peripheral nervous system safety signals of antibody–drug conjugates: cross-database reproducibility and labeling gaps identified using FAERS, JADER, and CVARD
2026
·
Xiaojie Feng
, Yabin Qin
, et al.
·
Frontiers in Pharmacology
·
1
PDF
Synthesis and evaluation of Urolithins derivatives as anticancer agents for hepatocellular carcinoma: In vitro, molecular docking, and dynamics simulations
2026
·
Jiahao Tan
, Ying Zheng
, et al.
·
Bioorganic Chemistry
·
1
Cost-effectiveness of tremelimumab plus durvalumab versus sorafenib for unresectable hepatocellular carcinoma in China: an economic evaluation based on five-year overall survival data from the HIMALAYA trial
2026
·
Rui Feng
, Ping Liang
, et al.
·
Frontiers in Public Health
PDF
Economic evaluation of newly approved cetuximab biosimilars for first-line treatment of RAS/BRAF wild-type metastatic colorectal cancer in China
2026
·
Rui Feng
, Liman Huo
, et al.
·
Frontiers in Oncology
PDF
Cost-effectiveness of nivolumab plus ipilimumab versus lenvatinib or sorafenib for unresectable hepatocellular carcinoma in China: a modeling study with price threshold analysis
2026
·
Rui Feng
, Liman Huo
, et al.
·
Frontiers in Pharmacology
PDF
Cost–utility and price threshold analysis of sacituzumab tirumotecan versus single-agent chemotherapy for previously treated metastatic triple-negative breast cancer in China
2026
·
Liman Huo
, Xiaojie Feng
, et al.
·
Frontiers in Public Health
PDF
Cost-effectiveness of ramucirumab plus paclitaxel as maintenance therapy for patients with advanced HER2-negative gastric or gastroesophageal junction cancer
2026
·
Dong Li
, Xue Zhao
, et al.
·
Frontiers in Oncology
PDF
Study on the Mechanism of Acacetin in Treating Hepatocellular Carcinoma Based on Network Pharmacology, Molecular Docking, Molecular Dynamics Simulation, and in Vitro Experiments
2025
·
Hong Liu
, Jing Bai
, et al.
·
Natural Product Communications
Show more works
View as search
Works count:
13
Citation count:
25
H-index:
2
I10-index:
1
Year
Topic
Type